Search clinical trials for: 1st Line

Total 9857 results

Swiss Group for Clinical Cancer Research

Active, not recruiting

SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II

Non-small Cell Lung Cancer | Malignant Pleural Mesothelioma

Switzerland
Swiss Group for Clinical Cancer Research

Active, not recruiting

1st Line Durvalumab in PS 2 NSCLC Patients

NSCLC Stage IV | NSCLC Stage IIIB

Switzerland
Academic Thoracic Oncology Medical Investigators...
AstraZeneca

Completed

A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients

Non-Small Cell Lung Cancer NSCLC

United States
University of Rochester

Completed

Enzalutamide & Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer.

Prostate Cancer

United States
Aadi Bioscience, Inc.

Completed

Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer

Colorectal Cancer Metastatic

United States
Daehwa Pharmaceutical Co., Ltd.

Active, not recruiting

Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy (OPTIMAL)

Recurrent or Metastatic Breast Cancer

China, Korea, Republic of, Serbia, Bulgaria, Hungary
Hellenic Institute for the Study of Sepsis

Completed

Bezlotoxumab Yielded Outcomes by Addressing Personalized Needs in Clostridioides Difficile Infection (BEYOND)

Mortality | Clostridioides Difficile Infection | Organ Dysfunction Syndrome | Stool Microbiome | Clostridioides Difficile Infection Recurrence

Greece
Pfizer

Completed

A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

Breast Neoplasms

United States, Canada, Spain, United Kingdom, Australia, Belgium, Korea, Republic of, Japan, Czechia, France, Germany, Hungary, Ireland, Italy, Poland, Russian Federation, Taiwan, Ukraine
Pfizer

Completed

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Non-small Cell Lung Cancer With EGFR-Activating Mutations

Italy, Poland, China, Hong Kong, Spain, Korea, Republic of, Japan
Ludwig-Maximilians - University of Munich

Active, not recruiting

FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC (AIO-KRK-0116)

Metastatic Colorectal Cancer

Germany
ppharmaand GmbH
Bristol-Myers Squibb; Gynecologic Oncology Group; European Network of Gynaecological... and other collaborators

Active, not recruiting

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal | Newly Diagnosed | FIGO Stage III-IV | Partial Response | Complete Response

United States, United Kingdom, Korea, Republic of, Russian Federation, Canada, Denmark, Taiwan, New Zealand, Ireland, Japan, Spain, Australia, Israel, Italy, Greece, Sweden, Czechia, Finland, Poland, Belgium, Germany, Romania, Singa... and more
Novartis Pharmaceuticals

Completed

A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies

Advanced Non-small Cell Lung Cancer

Spain, Canada, Germany, Korea, Republic of, Taiwan, United States, Japan, Netherlands, Singapore
ARCAGY/ GINECO GROUP

Terminated

1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer

First Line Metastatic Breast Cancer

France
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma (JS001)

Metastatic Melanoma | Unresectable Melanoma

China
Federation Francophone de Cancerologie Digestive
UNICANCER; GERCOR - Multidisciplinary Oncology Cooperative Group

Active, not recruiting

PHASE III RANDOMISED TRIAL TO EVALUATE FOLFOX WITH OR WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY FOR LOCALLY ADVANCED OR METASTATIC OESOPHAGO-GASTRIC CARCINOMA (GASTFOX)

OESOPHAGO-GASTRIC CARCINOMA

France, Martinique
AIO-Studien-gGmbH
Amgen; ClinAssess GmbH

Completed

Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer (PanaMa)

Metastatic Colorectal Cancer

Germany
Pfizer

Active, not recruiting

A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]

Breast Neoplasms

China, Taiwan, Hong Kong, Singapore, Thailand
Pfizer
Analysis Group; IMDC group

Completed

Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments

Metastatic Renal Cell Carcinoma (mRCC)

Canada
Bayer

Terminated

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3)

Uterine Fibroids

United States, Singapore, China, Malaysia, Israel, South Africa, Bulgaria, Czechia, New Zealand
Pfizer

Active, not recruiting

Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Systemic First-line (1st Line) Anti-cancer Treatment Under Daily Routine in Germany: Retrospective Medical Chart Review (RENALISTIC Study).

Carcinoma, Renal Cell

United States
Pfizer

Completed

Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting (ADONIS)

Metastatic Renal Cell Carcinoma (mRCC)

Spain, Italy, Belgium, France, United Kingdom, Austria, Greece, Netherlands
Sirtex Medical

Completed

SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma (SIRCCA)

Intrahepatic Cholangiocarcinoma

France, United Kingdom, Belgium, Australia, Spain, United States, Italy, Netherlands
Dr. Eliza Hawkes
Bristol-Myers Squibb

Active, not recruiting

Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A (1stFLOR)

Follicular Lymphoma

Australia
AIO-Studien-gGmbH
Servier Deutschland GmbH; Crolll Gmbh

Active, not recruiting

2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy (PREDICT)

Metastatic Pancreatic Cancer | Locally Advanced Pancreatic Cancer

Germany
Arcagy Research
Belgian Gynaecological Oncology Group; Grupo Español de Investigación en Cáncer... and other collaborators

Completed

Platine, Avastin and OLAparib in 1st Line (PAOLA-1)

Ovarian Cancer

France, Germany, Austria, Denmark, Italy, Japan, Finland, Spain, Monaco, Sweden, Belgium
Princess Anna Mazowiecka Hospital, Warsaw, Poland
Nutricia Foundation

Active, not recruiting

The Effect of Early Versus Standard Central Line Removal on Growth of Very Low Birth Weight Premature Infants

Growth Failure | CLABSI - Central Line Associated Bloodstream Infection

Poland
Novartis Pharmaceuticals
GlaxoSmithKline

Completed

A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

Neoplasms, Breast

Belgium, United Kingdom, Croatia, Hungary, Argentina, Australia, Germany, Israel, Japan, Poland, Russian Federation, Spain, France, Korea, Republic of, Hong Kong, United States, Brazil, Bulgaria, China, India, Ireland, Italy, Philip... and more
Bristol-Myers Squibb

Active, not recruiting

Real-Life Effectiveness and Safety in Participants With Advanced/Metastatic Renal Cell Carcinoma Starting 1st Line Nivolumab and Ipilimumab Combination Therapy or Nivolumab Monotherapy After Prior Therapy

Renal Cell Carcinoma

Germany
University of Turin, Italy
Tesaro, Inc.

Completed

Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1st-line Platinum-based Chemotherapy

Urothelial Carcinoma

Italy
Pfizer

Completed

Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer

Kidney Neoplasms

United States, China, Malaysia, India, Taiwan, Russian Federation, Mexico, Bosnia and Herzegovina, South Africa, Bulgaria, Chile, Philippines, Romania, Ukraine
Kasr El Aini Hospital

Completed

Triplet (FOLFOXIRI) vs. Doublet (FOLFOX or FOLFIRI) Regimen as a 1st Line Treatment in Metastatic Colorectal Carcinoma

Metastatic Colorectal Cancer

Egypt
Mylan Inc.
Mylan GmbH

Completed

Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca. (HERiTAge)

Breast Cancer

Slovakia, Brazil, Chile, Georgia, Hungary, India, Latvia, Peru, Romania, Russian Federation, Serbia, South Africa, Thailand, Turkey, Ukraine
Centre Oscar Lambret
University Hospital, Lille

Terminated

Correlation Between Tissue and Plasmatic EGFR in CBNPC With EGFR Mutation or Predictive Factor of EGFR Mutation (CONCORDE)

Nsclc

France
Swiss Group for Clinical Cancer Research

Terminated

Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer

Adenocarcinoma | Breast Cancer

Switzerland
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy

Malignant Mesothelioma

United States
Swiss Group for Clinical Cancer Research
The Belgian Society of Medical Oncology

Terminated

Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC

Breast Cancer

Switzerland, Belgium, Austria
Translational Research Center for Medical Innovation...
Kyoto Breast Cancer Research Network

Completed

Eribulin Treatment as 1st-line or 2nd-line Chemotherapy for HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer (E-SPEC)

Breast Cancer

Japan
Federation Francophone de Cancerologie Digestive

Completed

Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

France
Seagen Inc.
Millennium Pharmaceuticals, Inc.

Completed

A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

Disease, Hodgkin

United States, United Kingdom, France, Romania, Poland, Italy, Bulgaria, Hungary, Russian Federation, Czechia, Spain, Germany, Serbia
AstraZeneca

Completed

Real World Evidence of PD-L1, TMB Prevalence and Efficacy of 1st Line Chemotherapy in These High or Low Population for Stage IV Urothelial Cancer (YODO)

Urologic Neoplasms

Japan
Amgen

Completed

ObservationaL Study on the Qol of RAS Wild-type mCRC Patients Receiving Anti-EGFR MAbs + FOLFOX or FOLFIRI as 1st Line (SILQ)

Metastatic Colorectal Cancer

Italy
Federation Francophone de Cancerologie Digestive
Roche Pharma AG

Completed

1st Line Chemotherapy Alone or With Bevacizumab in Treating Older Patients With Metastatic Colorectal Cancer

Colorectal Cancer

France
OncoMed Pharmaceuticals, Inc.
Celgene Corporation

Completed

Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma (YOSEMITE)

Pancreatic Cancer

United States, Canada, United Kingdom, Spain, Australia, Belgium
OncoMed Pharmaceuticals, Inc.
Novotech (Australia) Pty Limited

Completed

A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer

Pancreatic Cancer

Australia, New Zealand, Spain
OncoMed Pharmaceuticals, Inc.
Novotech (Australia) Pty Limited

Completed

A Study of FOLFIRI Plus OMP-21M18 as 1st or 2nd-line Treatment in Subjects With Metastatic Colorectal Cancer

Colorectal Cancer

Australia, New Zealand
European Organisation for Research and Treatment...
PharmaMar

Terminated

Trabectedin Maintenance Post 1st-line in STS

Sarcoma, Soft Tissue

France, Germany, Spain, Netherlands, Poland, United Kingdom
Celgene

Completed

Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer

Squamous Cell Carcinoma, Non-Small-Cell Lung

United States, Spain, Germany, Italy, United Kingdom
Amgen

Completed

AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib

Advanced Renal Cell Carcinoma
Boehringer Ingelheim

Completed

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Lung Neoplasms

Hong Kong, Korea, Republic of, Spain, Singapore, China, United Kingdom, Taiwan, Canada, Australia, Germany, Ireland, Sweden, France, Norway
Asan Medical Center
Ulsan University Hospital; Bundang CHA Hospital

Completed

Retrospective Analysis of 2nd-line Nab-Paclitaxel + Gemcitabine After 1st-line FOLFIRINOX in Pancreatic Cancer

Pancreatic Cancer | Metastatic Pancreatic Cancer

Korea, Republic of

Search clinical trials for: 1st Line

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Russia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations